Pique Therapeutics is a biotechnology company seeking to become the leading therapeutic vaccine company, focused initially on the treatment of cancer.
Pique's lead product is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer (NSCLC). PT 107 has completed Phase 1 clinical trials, was well-tolerated, and had an excellent safety profile in cancer patients. PT 107 showed a 134% improvement in median survival (11 months) for patients with late-stage NSCLC, as compared with the expected 4 to 6 months. Remarkably, almost 25% of the patients are still alive and in remission after 3 years.
PT 107 is currently in a two-arm, double-blind Phase 2 study, to further examine the safety and efficacy of the drug.
Pique is also utilizing its novel therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.
The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami. |